Conference Summaries: Day Two<BR> Tuesday, February 6, 2001

The Body Covers: The 8th Conference on Retroviruses and Opportunistic Infections

Conference Summaries: Day Two
Tuesday, February 6, 2001

Hear the Lectures from The 8th Conference on Retroviruses and Opportunistic Infections
Hear the Symposia from The 8th Conference on Retroviruses and Opportunistic Infections
Search through the conference's original abstracts

HIV-Related Peripheral Neuropathies and Their Treatment (Session 31)
Coverage by Keith Henry, M.D.
- HIV-Related Peripheral Neuropathies and Their Treatment (State-of-the-Art Lecture L8)
Epidemiology and Infection Control (Session 32)
Coverage by Andrew T. Pavia, M.D.
- Bacterial STDs and Sexual Mixing of HIV-Discordant Men Who Have Sex with Men: A Recipe for HIV Transmission (Slide Session 262)
- The Probability of HIV-1 Transmission Per Coital Act in Monogamous HIV-Discordant Couples, Rakai, Uganda (Slide Session 266)
Coverage by Calvin Cohen, M.D.
- Continued Low Mortality and Morbidity, and HAART Utilization among HIV-Infected Patients in the HIV Outpatient Study (HOPS) (Slide Session 268B)
Maternal-Fetal Transmission of HIV-1: Implications for Care of HIV-Affected Women and Children (Session 36)
Coverage by Andrew T. Pavia, M.D.
- Update on Prevention of Mother-to-Child HIV Transmission: U.S. Successes, International Challenges (Symposium S12)
- Immunologic Reconstitution in Children and Adolescents Treated with HAART (Symposium S15)
Structured Treatment Interruption: Novel Strategy or Oxymoron (Session 37)
Coverage by Pablo Tebas, M.D.
- Prolonged HAART Initiated Within 120 Days of Primary HIV-1 Infection Does Not Result in Sustained Control of HIV-1 After Cessation of Therapy (Slide Session 288)
- Outcome after 1 Year of HAART, 3 Cycles of STI, and 12 Months Off Therapy Versus Natural Evolution Without ART in Early Chronic HIV-1 Infection (CHI): A Case-Control Study (Slide Session 289)
Trends in Morbidity and Mortality (Session 38)
Coverage by Pablo Tebas, M.D.
- Causes of Death Among HIV-Infected Patients in the Era of Highly Active Antiretroviral Therapy (HAART). Aquitaine Cohort (France), 1998-1999 (Poster 299)
Antiretroviral Chemotherapeutic Agents: Preclinical Studies (Session 39)
Coverage by Judith Feinberg, M.D.
- Low Concentrations of Mycophenolic Acid Augment the Antiretroviral Activity of Abacavir (ABC), Didanosine (ddI), Tenofovir (TFV), and the Combination of ABC and ddI In Vitro (Poster 307)
Clinical Trials of HIV-1 Reverse Transcriptase Inhibitors (Session 40)
Coverage by Keith Henry, M.D.
- START Observational Study: Longitudinal Follow-Up of Virologic and Immunologic Responses in START I and START II Patients (Poster 314)
- Efficacy of Combivir (COM) (Lamivudine 150mg/ Zidovudine 300mg) plus Ziagen (Abacavir (ABC) 300mg) BID Compared to Trizivir (TZV) (3TC 150mg/ZDV 300mg/ABC 300mg) BID in Patients Receiving Prior COM plus ABC (Poster 315)
- Use of Trizivir to Simplify Therapy in HAART- Experienced Patients with Long-Term Suppression of HIV-RNA: TRIZAL Study (AZL30002) -- 24- Week Results (Poster 316)
Coverage by Richard Alan Elion, M.D.
- Efficacy and Safety of Switch to 3TC 300mg QD vs. Continued 3TC 150mg BID in Subjects with Virologic Suppression on Stable 3TC/d4T/PI Therapy (COLA4005): Final 24-Week Results (Poster 317)
- Comparison of HIV RNA Suppression Produced by Triple Regimens Containing Either Didanosine Enteric-Coated or Didanosine Tablet Formulations Each Administered Once Daily (Poster 318)
- Comparison of a Triple Combination Regimen Containing an Enteric-Coated Formulation of Didanosine Administered Once Daily Versus a Regimen of Combivir Plus Nelfinavir (Poster 319)
- Long-Term Virologic and Immune Responses in Subjects Maintained on Exclusive Nucleoside Analog (NRTI)-Based Therapy in ACTG 364 (Poster 322)
Coverage by Benjamin Young, M.D.
- Once-a-Day Treatment for HIV Infection: Final 48-Week Results (Poster 320)
Coverage by Judith Feinberg, M.D.
- Once-Daily Combination Therapy with Emtricitabine, Didanosine, and Efavirenz in Treatment-Naive HIV-Infected Adults: 64-Week Follow-Up of the ANRS 091 Trial (Poster 321)
- Low Two-Year Risk of Virologic Failure with First Regimen HAART (Poster 325)
Coverage by Brian Boyle, M.D.
- A Randomized, Open, Multicenter Trial Comparing Combivir plus Nelfinavir or Nevirapine in HIV-Infected Naive Patients (The Combine Study) (Poster 327)
Clinical Trials of HIV-1 Protease Inhibitors (Session 41)
Coverage by Keith Henry, M.D.
- Amprenavir (APV) 600mg/Ritonavir (RTV) 100mg BID or APV 1200mg/RTV 200mg QD Given in Combination with Abacavir (ABC) and Lamivudine (3TC) Maintains Efficacy in ART- Naive HIV-1-Infected Adults over 12 Weeks (APV20001) (Poster 332)
Coverage by Pablo Tebas, M.D.
- GW433908, a Novel Prodrug of the HIV Protease Inhibitor (PI) Amprenavir (APV): Safety, Efficacy, and Pharmacokinetics (PK) (APV20001) (Poster 333)
Coverage by Paul E. Sax, M.D.
- Indinavir/Ritonavir Versus Indinavir in Combination with AZT/3TC for Treatment of HIV in Nucleoside-Experienced Patients: a Randomized, Open-Label Trial (Poster 335)
- Preliminary Results from Indinavir (IDV) and Ritonavir (RTV) in a Once-Daily Regimen (Marck 103/104) (Poster 336)
Antiretroviral Chemotherapy: When to Start (Session 42)
Coverage by Pablo Tebas, M.D.
- Effectiveness of Antiretroviral Therapy in the Elderly Compared to a Younger Cohort (Poster 340)
- Long-Term Survival After Initiation of Antiretroviral Therapy (Poster 341)
Immune-Based Therapy (Session 43)
Coverage by Brian Boyle, M.D.
- Prediction of CD4+Cell Response to Subcutaneous Recombinant Interleukin-2 (SCrIL-2) (Poster 343)
- Extended Therapy with Subcutaneous Interleukin-2 (scIL-2) in HIV-Infection: Long-Term Follow-Up of 3 Trials (Poster 347)
- Immunomodulation of Chronic HIV-1 Infection: Impact of HAART, Interleukin-2 and/or an Inactivated gp120-Depleted HIV-1 Immunogen (REMUNE) (Poster 349)
- Thalidomide Pharmacokinetics (PK), Safety and Effect on HIV Viral Load and Immune Parameters (Poster 352)
Coverage by Pablo Tebas, M.D.
- Mycophenolate Mofetil (MMF) Induces a Decrease in HIV-1 RNA Associated with Guanosine Depletion (Poster 351)
Treatment Interruption (Session 44)
Coverage by Paul E. Sax, M.D.
- Short-Cycle Intermittent HAART: A Pilot Study (Poster 354)
- A Randomized Controlled Trial of Intermittent Versus Continuous HAART (Poster 364)
Coverage by Calvin Cohen, M.D.
- The Effect of Treatment Interruption in Patients with Virologic Failure: Results from a Multi-Cohort Collaborative Study (Poster 365)
Immune Reconstitution (Session 45)
Coverage by Keith Henry, M.D.
- T-Lymphocyte Changes after Three Years of Controlled Viral Replication (Poster 372)
Viral Dynamics and Reservoirs (Session 46)
Coverage by Judith Feinberg, M.D.
- Viral Reservoirs after Two Years of Sustained Serum Viral Suppression in Patients in whom HAART Was Initiated Early: The Merck 060/ICC 004 Cohort (Poster 395)
Treatment of Primary Infection (Session 47)
Coverage by Judith Feinberg, M.D.
- The Effect of Pre-Treatment on Success of HAART Among Patients with Primary HIV (Poster 401)
Coverage by Keith Henry, M.D.
- The Safety and Efficacy of a Ritonavir-Boosted Amprenavir-Based Regimen After Switch from Amprenavir-Based HAART (Poster 405)
Coverage by Pablo Tebas, M.D.
- A Randomized Trial of Interleukin-2 (IL-2) Added to HAART for Primary HIV (Poster 407)
Coverage by Richard Alan Elion, M.D.
- Thymic Reconstitution in Primary HIV Infection (PHI) following HAART Is Polyclonal (Poster 409)
Clinical, Viral, and Immunological Features of Primary Infection (Session 48)
Coverage by Judith Feinberg, M.D.
- Clinical Features of Acute Retroviral Syndrome (ARS) by Gender and Age. (Poster 413)
Drug Resistance in Primary Infection (Session 49)
Coverage by Calvin Cohen, M.D.
- Prevalence of Drug-Resistant HIV-1 Variants in Newly Infected Individuals during 1999-2000 (Poster 423)
Regimen Failure (Session 50)
Coverage by Richard Alan Elion, M.D.
- Incidence and Predictors of Clinical Progression Among HIV-Infected Patients Experiencing Virologic Failure of Protease Inhibitor-Based Regimens (Poster 428)
Clinical Utility of Resistance Testing (Session 51)
Coverage by Calvin Cohen, M.D.
- A Prospective, Randomized Study on the Usefulness of Genotypic Resistance Testing and the Assessment of Patient-Reported Adherence in Unselected Patients Failing Potent HIV Therapy (ARGENTA): Final 6-Month Results (Poster 433)
Coverage by Benjamin Young, M.D.
- Phenotypic Susceptibility and Virologic Responses in Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Experienced Subjects Receiving NRTIs + Efavirenz (EFV), Nelfinavir (NFV), or Both in ACTG 364 (Poster 435)
- Genotypic Resistance at Baseline Fails to Predict Outcome Among Chronically Infected, Antiretroviral-Therapy-Naive Patients in Two Large Trials of PI-Based Regimens (Poster 439)
Resistance to Antiretroviral Drugs (Session 52)
Coverage by Calvin Cohen, M.D.
- Virologic Suppression from Different Thymidine Analogue (TA)-Containing HAART Regimen Sequencing Strategies: VIRA 3001 (Poster 444)
- Viral Resistance Results from the International, Multicenter, Randomized, Placebo-Controlled, 48-Week Study of Hydroxyurea (HU) or Placebo Combined with Efavirenz (EFV), Didanosine (ddl) and Stavudine (d4T) in Treatment-Naive and -Experienced Patients (Poster 445)
Coverage by Benjamin Young, M.D.
- Time to Appearance of NRTI-Associated Mutations and Response to Subsequent Therapy for Patients on Failing ABC/COM (Poster 448)
- Plasma Trough Levels Correlate with Distinct Genetic Mechanisms During the Development of Amprenavir Resistance (Poster 465)
- Molecular Mechanism of I50V HIV-1 Protease Resistance and Cross-Resistance to Protease Inhibitors (Poster 466)
HIV Pathogenesis (Session 56)
Coverage by Paul E. Sax, M.D.
- Antiretroviral Intensification Accelerates the Decay of the Latent Reservoir of HIV-1 and Decreases but Does Not Eliminate Ongoing Virus Replication (Slide Session 502)

Previous Day's Sessions | Next Day's Sessions

Return to The Body's coverage of
The 8th Conference on Retroviruses and Opportunistic Infections.

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.